Placebo + Upadacitinib for alopecia areata

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 25 Aug 2023: Trial registered, NCT06012240
  2. 11 Oct 2023: Trial started, NCT06012240

The trials

NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

State
Under way
Phase
Phase 3
People
1,500 planned
Started
11 Oct 2023
Primary completion
Apr 2030
Arms
Study 1: Group 4 Upadacitinib Dose A, Study 1: Group 5 Upadacitinib Dose B, Study 2: Group 4 Upadacitinib Dose A, Study 2: Group 5 Upadacitinib Dose B
Results
None posted
Papers
doi:10.1001/jamadermatol.2026.2853
  1. 25 Aug 2023: Trial registered
  2. 11 Oct 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.